Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X L Wei

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 22, 2019
Over-expression of both VEGF-C and Twist predicts poor prognosis in human breast cancerY-Q Zhang, W-L Chen, F Zhang, et al.
Scientific Reports|March 11, 2017
Influence of dairy by-product waste milk on the microbiomes of different gastrointestinal tract components in pre-weaned dairy calvesY F Deng, Y J Wang, Y Zou, et al.
ESMO Open|July 26, 2024
Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trialsF-R Liu, X-L Wei, W-N Feng, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 7, 2023
[A single-center study on the distribution and antibiotic resistance of pathogens causing bloodstream infection in patients with hematological malignancies]L J Cai, X L Wei, Y Q Wei, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|January 29, 2018
[Risk factors related to HIV new infections among men who have sex with men in a cohort study]W Guo, Y Li, N Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2019
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F Wang, X L Wei, F H Wang, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 22, 2019
Over-expression of both VEGF-C and Twist predicts poor prognosis in human breast cancerY-Q Zhang, W-L Chen, F Zhang, et al.
Scientific Reports|March 11, 2017
Influence of dairy by-product waste milk on the microbiomes of different gastrointestinal tract components in pre-weaned dairy calvesY F Deng, Y J Wang, Y Zou, et al.
ESMO Open|July 26, 2024
Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trialsF-R Liu, X-L Wei, W-N Feng, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 7, 2023
[A single-center study on the distribution and antibiotic resistance of pathogens causing bloodstream infection in patients with hematological malignancies]L J Cai, X L Wei, Y Q Wei, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|January 29, 2018
[Risk factors related to HIV new infections among men who have sex with men in a cohort study]W Guo, Y Li, N Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2019
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F Wang, X L Wei, F H Wang, et al.
Pageof 6